Compare Davita Inc (DVA) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs MasterCard Inc — how do they compare? Davita Inc trades at $178.35 (market cap $11.72B), while MasterCard Inc trades at $562.59 (market cap $493.34B). The key difference: MasterCard Inc is far larger — about 42.1× Davita Inc's market cap, and MasterCard Inc pays a 0.62% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | MA | |
|---|---|---|
Market Cap | $11.72B | $493.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $598.96 |
52-Week Low | $103.87 | $471.55 |
Enterprise Value | $24.44B | $506.38B |
Volume | — | 4,635,698 |
Dividend Yield | — | 0.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Mastercard (MA) trades at $561.44, down 0.27% on the day, with a bullish technical signal supported by moving averages and key support at $560. The company demonstrates robust fundamentals, with revenue growing to $32.79B in 2025 and a net income margin of 46.34%. Recent earnings beats and a strong analyst consensus highlight positive momentum amid expansion in digital payments and AI initiatives.
The outlook for MA remains favorable due to consistent earnings growth, high profitability, and strategic positioning in payment technology. Risks include competitive disruption from stablecoins and regulatory challenges. With a consensus price target of $660.85 and no sell ratings, Wall Street sentiment is strongly bullish, though investors should monitor execution on innovation and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
